Physician profile
Mainuddin Ahmed
NPI 1790739688
$2,398.73
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,911 · 2020: $476 · 2021: $11.92.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $260.14 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $242.91 | 2019-2020 | |
| Incyte Corporation | $183.47 | 2019-2020 | |
| Exelixis INC. | $122.42 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $115.90 | 2019 | |
| Astellas Pharma US INC | $111.79 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $109.39 | 2019-2020 | |
| Genzyme Corporation | $109.24 | 2019 | |
| Novartis Pharmaceuticals Corporation | $97.78 | 2019-2020 | |
| Daiichi Sankyo INC. | $93.69 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $85.00 | 2019 | |
| Amgen INC. | $84.37 | 2019-2020 | |
| Eisai INC. | $80.46 | 2019 | |
| Celgene Corporation | $78.28 | 2019-2020 | |
| Tesaro, INC. | $51.85 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $51.41 | 2019-2020 | |
| Pfizer INC. | $50.27 | 2019 | |
| Genentech USA, INC. | $44.94 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.62 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $40.88 | 2019 | |
| Alexion Pharmaceuticals, INC. | $36.00 | 2019 | |
| Puma Biotechnology, INC. | $34.07 | 2020 | |
| Dova Pharmaceuticals | $30.05 | 2019 | |
| Lilly USA, LLC | $28.93 | 2019 | |
| Gilead Sciences, INC. | $25.61 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $20.98 | 2019 | |
| Rigel Pharmaceuticals, INC. | $20.79 | 2019 | |
| Taiho Oncology, INC. | $20.02 | 2019 | |
| Clovis Oncology, INC. | $18.44 | 2020 | |
| Array Biopharma INC | $16.02 | 2019 | |
| Kite Pharma, INC. | $15.35 | 2020 | |
| Emd Serono, INC. | $14.67 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.27 | 2019 | |
| Seagen INC. | $14.11 | 2019 | |
| Foundation Medicine, INC. | $11.54 | 2019 | |
| Mylan Institutional INC. | $11.11 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $10.96 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mainuddin Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.